We’re already actively working with pharma and biotech partners – we’ve demonstrated profound efficacy enhancements in pre-clinical studies and we’re planning translation of these into clinical development programs.
By combining your therapeutic agent with SonoTran® we could significantly de-risk your clinical development program and maximise its chances of delivering first-in-class and/or best-in-class therapy to patients. Importantly no drug reformulation is needed whatsoever.
We’ll manage the installed based of SonoTran® Systems so that we as partners can focus on the development and commercialization of the injectable therapeutic agent and SonoTran® Particles.
By working with us, we can create new IP and optimal pricing and reimbursement that together provide a framework to bring better and smarter therapies to patients.